Senti Biosciences (NASDAQ:SNTI) Releases Quarterly Earnings Results, Misses Expectations By $0.16 EPS

Senti Biosciences (NASDAQ:SNTI – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.16), reports.

Senti Biosciences Stock Down 0.4%

NASDAQ:SNTI traded down $0.00 on Wednesday, hitting $0.10. The stock had a trading volume of 160,373 shares, compared to its average volume of 1,181,995. The stock has a market cap of $3.01 million, a price-to-earnings ratio of -0.05 and a beta of 2.31. The business’s 50-day simple moving average is $0.25 and its two-hundred day simple moving average is $0.67. Senti Biosciences has a 52-week low of $0.09 and a 52-week high of $2.88.

Senti Biosciences shares are set to reverse split on the morning of Thursday, November 19th. The 1-33 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, November 18th.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Get Our Latest Stock Report on Senti Biosciences

Senti Biosciences Company Profile

(Get Free Report)

Senti Biosciences is a biotechnology company focused on developing cell and gene therapies using synthetic biology. Its platform uses engineered gene circuits designed to help therapeutic cells recognize disease-related signals and respond in a controlled way. The company has worked on engineered immune-cell treatments, including allogeneic CAR-NK candidates. Its pipeline has included programs aimed at blood cancers and solid tumors, such as SENTI-202 and SENTI-301A. Founded in 2016 and based in South San Francisco, California, Senti Biosciences has concentrated its research and development activities in the United States.

See Also

Earnings History for Senti Biosciences (NASDAQ:SNTI)

Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.